Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Bimiralisib in Advanced Solid Tumors
NCT02483858Phase 1Completed
- Sponsor
- PIQUR Therapeutics AG
- Start
- Mar 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bimiralisib in solid tumor and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by PIQUR Therapeutics AG. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate. Started Mar 2019; status: completed.
02
Drugs
bimiralisib
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02483858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483858.